

\$34.82+ Billion U.S. Pain Management Drugs Market - Allied Market Research

PORTLAND, OREGON, UNITED STATES,
July 17, 2024 /EINPresswire.com/ -- [U.S. Pain Management Drugs Market](#)
Insight (2024-2031)

Market Overview:

- Market Size & Growth:
- Valued at \$25.17 billion in 2021.
- Projected to reach \$34.82 billion by 2031.
- CAGR: 3.3% from 2022 to 2031.

Pain Definition:

- Unpleasant sensory and emotional experience.
- Causes: acute (short-term) and chronic (long-term) pain.
- Sources: bone & joint conditions, nerve damage, injuries.

Historical Overview:

- Analysis from 2021-2031 shows consistent growth.
- Factors: Effective distribution, awareness, new drug approvals.

Market Dynamics:

- Opportunities:
- Growing health-conscious consumer base.
- Enhanced healthcare infrastructure.
- Rising geriatric population with chronic diseases.
- Challenges:
- COVID-19 disruption on supply chains and surgeries.
- Side effects and misuse of pain medications.

Key Factors Influencing Market Growth:

- Positive Influences:



\$34.82+ Billion U.S. Pain Management Drugs Market - Allied Market Research

- Increased prevalence of diabetic neuropathies.
- Rising incidents of sports injuries and back pain.
- Substantial government spending on pain management.
- Growing awareness and counseling on pain management.
- E-commerce promoting easier access to pain medications.
- Negative Influences:
 - Availability of alternative therapies.
 - Habit-forming potential and side effects of drugs.

Segmental Overview:

- By Drug Class:
 - NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, nonnarcotic analgesics.
 - Opioids segment leads, expected to remain dominant.
- By Indication:
 - Categories: arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, etc.
 - Postoperative pain segment dominates; cancer pain expected to grow significantly.
- By Pain Type:
 - Chronic and acute pain.
 - Chronic pain segment holds highest revenue and growth projection.

Competitive Landscape:

- Major Players:
 - Pfizer Inc, Viatrix (Mylan N.V.), Eli Lilly and Company, Novartis AG, and others.
- Key Strategies:
 - Agreements, product approvals, collaborations, partnerships.
 - Example: Myovant Sciences and Pfizer's Myfembree approval in 2022.
- Innovations:
 - Focus on non-opioid, non-addictive therapeutics.
 - Investment in research for abuse-deterrent formulations.

Market Recovery Post-COVID-19:

- Gradual recovery anticipated post-2021.
- Factors: Increased adoption of low side-effect pain medications, rise in pending surgeries, and new drug approvals.

□□□□□□ □□□□□□ □□□□□□: <https://www.alliedmarketresearch.com/purchase-enquiry/A09451>

David Correa

Allied Market Research

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/728252659>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.